2. Academic Validation
  3. Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control

Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control

  • NPJ Vaccines. 2022 Jun 23;7(1):64. doi: 10.1038/s41541-022-00484-y.
Elena Tondini # 1,  Niels R M Reintjens # 2,  Giulia Castello 1,  Tsolere Arakelian 1,  Marjolein Isendoorn 2,  Marcel Camps 1,  Jana Vree 1,  Gijs A van der Marel 2,  Dmitri V Filippov 2,  Jeroen D C Codee 3,  Ferry Ossendorp 4
Affiliations

Affiliations

  • 1 Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.
  • 2 Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands.
  • 3 Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands. jcodee@chem.leidenuniv.nl.
  • 4 Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. f.a.ossendorp@lumc.nl.
  • # Contributed equally.
PMID: 35739113 DOI: 10.1038/s41541-022-00484-y
Abstract

Adjuvants play a determinant role in Cancer vaccination by optimally activating APCs and shaping the T cell response. Bacterial-derived lipid A is one of the most potent immune-stimulators known, and is recognized via Toll-like Receptor 4 (TLR4). In this study, we explore the use of the synthetic, non-toxic, lipid A analog CRX-527 as an Adjuvant for peptide Cancer vaccines. This well-defined Adjuvant was covalently conjugated to antigenic Peptides as a strategy to improve vaccine efficacy. We show that coupling of this TLR4 Agonist to peptide antigens improves vaccine uptake by dendritic cells (DCs), maturation of DCs and T cell activation in vitro, and stimulates DC migration and functional T cell priming in vivo. This translates into enhanced tumor protection upon prophylactic and therapeutic vaccination via intradermal injection against B16-OVA melanoma and HPV-related TC1 tumors. These results highlight the potential of CRX-527 as an Adjuvant for molecularly defined Cancer vaccines, and support the design of adjuvant-peptide conjugates as a strategy to optimize vaccine formulation.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z